Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.50 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452258 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL2910722 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL8668203 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL1618939 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL8060342 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL11337304 | 1.00 | CYP1A2 (0.60) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL10337684 | 0.80 | CYP1A2 (0.57) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL2636177 | 0.80 | CYP1A2 (0.62) | CYP1A2HDAC1LMNAMAPTHDAC3 | |
| SCHEMBL5311482 | 0.80 | NFE2L2 (0.55) | MAOB | |
| SCHEMBL5311487 | 0.80 | NFE2L2 (0.55) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0380689-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HYDROXY-4-PHENYL-3-BUTENOIC ACID | DAICEL CHEM (JP) | 1995-10-04 | — | — | EP | claimed |
| US-5429935-A | Reduction of the corresponding ketone with microorganisms | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1995-07-04 | — | — | US | claimed |
| US-5288620-A | Reducing 2-oxo-4-phenyl-3-butenoic acid with enzyme preparation derived from microorganisms | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-22 | — | — | US | claimed |
| US-5194380-A | Treatment with a microorganism | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-16 | — | — | US | claimed |
| EP-0380689-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HYDROXY-4-PHENYL-3-BUTENOIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-08-08 | — | — | EP | claimed |
| JP-6197774-A | — | — | None | — | — | JP | disclosed |
| US-7820847-B2 | Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2006-08-10 | — | — | US | disclosed |
| EP-1658260-A1 | BUTENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE FOR THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES | Merk Patent Gmbh (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005014521-A1 | BUTENOIC ACID DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USE FOR THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES | MERK PATENT GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| EP-0620857-B1 | SYNTHESIS OF HOMOCHIRAL 2-HYDROXY ACIDS | GENZYME LTD (GB) | 2000-08-02 | — | — | EP | disclosed |
| US-5686275-A | LACTATE DEHYDROGENASE | GENZYME LTD. (GB) | 1997-11-11 | — | — | US | disclosed |
| US-5288620-A | Reducing 2-oxo-4-phenyl-3-butenoic acid with enzyme preparation derived from microorganisms | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| US-5288620-A | Reducing 2-oxo-4-phenyl-3-butenoic acid with enzyme preparation derived from microorganisms | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| WO-1993013215-A1 | SYNTHESIS OF HOMOCHIRAL 2-HYDROXY ACIDS | GENZYME LIMITED (GB) | 1993-07-08 | — | — | WO | disclosed |
| US-5194380-A | Treatment with a microorganism | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| US-5194380-A | Treatment with a microorganism | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0380689-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HYDROXY-4-PHENYL-3-BUTENOIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
| EP-0380689-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HYDROXY-4-PHENYL-3-BUTENOIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
| WO-1990000613-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 2-HYDROXY-4-PHENYL-3-BUTENOIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178434-A1 | Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes | APOB, ALOX15, GPR119 | CYP1A2 414/4885HDAC1 3681/4885LMNA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.